Answer
It may increase metformin exposure by inhibiting MATE transporters. Clinicians should monitor for metformin-related adverse effects and review treatment if necessary.
Sources for this answer
- Evrysdi 0.75 mg/mL powder for oral solution — Current selected SmPCemc · Summary of Product Characteristics
- Evrysdi 5 mg film‑coated tablets — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.